Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
eltrombopag 12.5 milligrams · 1 trial · 1 indication
Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.
| Arm | Type | Description |
|---|---|---|
| low dose | EXPERIMENTAL | eltrombopag 12.5 mg/day |
| middle dose | EXPERIMENTAL | eltrombopag 25 mg/day |
| high dose | EXPERIMENTAL | eltrombopag 37.5 mg/day |
| Name | Type | Description |
|---|---|---|
| eltrombopag 12.5 milligrams (mg) tablet | DRUG | eltrombopag 12.5 mg tablet once a day |
| eltrombopag 25 mg tablet | DRUG | eltrombopag 25 mg tablet once a day |
Inclusion Criteria: * Subject who agree to comply with protocol requirements and instructions and who provide signed and dated written informed consent. * Male and female subjects, ≥20 years of age (at the time of informed consent) with chronic liver disease. * Child-Pugh score \<=9. * A baseline p...
Eltrombopag 12.5 milligrams is a low-dose tablet formulation of eltrombopag, a small molecule drug developed by GSK plc (ticker GSK). It is being studied in liver diseases, specifically in thrombocytopenic patients with chronic liver disease. The 12.5 mg strength is also referred to as the eltrombopag 12.5 mg tablet.
Eltrombopag 12.5 milligrams has been studied in thrombocytopenic patients with chronic liver disease. A Phase 2 pharmacokinetics trial evaluated the drug in this population in Japan. The condition studied was liver diseases, and the trial enrolled 38 subjects aged 20 years and older.
Eltrombopag 12.5 milligrams targets MPL, the thrombopoietin receptor. It acts as an MPL agonist, meaning it stimulates that receptor. This target class, agonist activity at MPL, is the basis for its study in thrombocytopenic patients with chronic liver disease.
Eltrombopag 12.5 milligrams is developed by GSK plc, which trades under the ticker GSK. GSK is the company associated with this low-dose eltrombopag tablet and the clinical program in liver diseases.
Eltrombopag 12.5 milligrams is in Phase 2 development. The single recorded trial, NCT00861601, is a completed Phase 2 pharmacokinetics study. It is an investigational asset in the clinical development stage for liver diseases, and no approval status is established by the available program information.
Eltrombopag 12.5 milligrams has been evaluated in one clinical trial, NCT00861601, titled a Phase 2 pharmacokinetics study of eltrombopag in Japanese thrombocytopenic subjects with chronic liver disease. That trial is completed, enrolled 38 participants, was randomized and controlled, and was conducted in Japan.